Fundación Cerebro y Mente

Staging Neuropsychiatric Disorders: Implications for Etiopathogenesis and Treatment

Mojácar (Almería)

October 14 - 18 2009

FINAL PROGRAMME

Tomás Palomo, Spain
Opening remarks
Patrick McGorry, Australia
Clinical staging: a heuristic framework for intervention and understanding the pathophysiological basis of disorders

Pierre Sokoloff, France
Beyond genes in neuropsychiatric disorders
Barry Keverne, UK
Epigenetically regulated imprinted genes in foetal programming
Renaud Massart, France
Epigenetic function of the GPCR GPR88 in cortical neurons
Janet Hoenicka, Spain
ANKK1 expression study: uncovering the biological bases of TaqIA-associated phenotypes
Eduardo Rodriguez-Farré, Spain
Biomarkers of neurodevelopmental exposure to methylmercury
Isidro Ferrer, Spain
Methylation of gene promoters in post-mortem brain tissue
Norbert Müller, Germany
Inflamatory biomarkers and depression

Thomas N Chase, USA
Apathy in brain disease: diagnosis, pathophysiology and treatment
Ian Reid, UK
Staging antidepressant treatment
Eduard Vieta, Spain
Staging bipolar disorders

Trevor Archer, Sweden
MPTP-induced deficits: Effects of Physical Exercise
Kurt A Jellinger, Austria
Staging in Alzheimer’s disease: implications for diagnosis and treatment
Kiminobu Sugaya, USA
Arresting progression of neurodegenerative disorder
Peter Riederer, Germany
Diabetes Type II: a risk factor for Depression - Parkinson - Alzheimer

Bita Moghaddam, USA
Behavioral differences between adolescents and adults are modulated by motivational factors
Patricio O´Donnell, USA
Adolescent maturation of cortical dopamine
Beatriz Luna, USA
Maturation of brain systems underlying the development of cognitive control from childhood to adulthood
Celso Arango, Spain
Longitudinal brain changes in chid and adolescent first-episode psychosis
Aysenil Belger, USA
The neuronal circuitry of autism
Louk Vanderschuren, The Netherlands
Neurobiology of social reward: insights from play behaviour in adolescent rats
Giovanni Laviola, Italy
Critical age windows in neurodevelopmental psychiatric diseases: evidence from animal models

In memoriam of Siegfried Tuinier
Richard Beninger, Canada
Antipsychotic medications and memory in newly diagnosed schizophrenic patients
Robin Murray, UK
Why look for animal models of schizophrenia when drug-induced psychosis provides such a good model?
Philip McGuire, UK
Brain imaging in the early stages of psychosis: from at risk mental state to first episode
Richard M Kostrzewa, USA
Stereotypic progressions in psychotic behaviour
Ralf Pukrop, Germany
Neurocognitive indicators for a transition to psychosis
José Luis Vázquez-Barquero, Spain
Clinical outcome following prescribed neuroleptic discontinuation in first episode psychosis
Anissa Abi-Dargham, USA
A focus on dopamine through the stages of schizophrenia

Klaus Ebmeier, UK
Imaging markers of mild cognitive impairment and Alzheimer ´s disease
Jennifer L Whitwell, USA
Progression of atrophy in Alzheimer’s disease and related disorders
Iván Izquierdo/ Jorge H Medina, Brazil
Mechanisms of memory persistence
José Maria Delgado, Spain
Functional basis of cognitive processes in transgenic mice
Paul Ince, UK
Patterns of alpha-synucleinopathy in Alzheimer’s disease
Martin Cammarota, Brazil
Ventral tegmental area regulates the persistent storage of fear-motivated memories
Carlos Acuña, Spain
Decision making, behavioral supervision and learning
Antonio Lobo, Spain
Staging of cognitive impairment and incidence of dementia: implications for prevention

Marina Wolf, USA
Progressive dysregulation of glutamate synapses in addiction
Peter Kalivas, USA
The glutamate homeostasis hypothesis of addiction
Anthony A Grace, USA
Stress, drug abuse and schizophrenia: common pathophysiological variables underlying dopamine system dysregulation
Charles Bradberry, USA
Modeling the emergence of addiction related cognitive impairment with longitudinal studies in monkeys
Robert M Post, USA
Mechanisms of illness progression in the recurrent affective disorders
Tomás Palomo, Spain
Concluding Remarks

Hoja de Inscripción (Obtener formulario en papel para su tramitación)

Hoja de envio de abstract

Inscripción Online

Abstract Online

Fundación Cerebro y Mente

c/ General Oraa, 47 - 1º E

28006 Madrid, España

Telf: +34 91 561 1267

Fax: +34 91 564 1817

Inscrita en el registro de fundaciones docentes y de investigación, MAD-1-3-601